ISRAELVALLEY SPECIAL. Elle fait partie des firmes israéliennes mondialement connues… mais que la presse francophone (même spécialisée) ignore totalement. La startup israélienne Viz.ai se valorise à 1,2 Md$. Elle est déjà active dans plus de mille hôpitaux dans le monde.
La société possède une expertise exceptionnelle dans l’intelligence artificielle médicale et vient de lever 100 M$ pour étendre sa plateforme de diagnostic et de coordination des soins.
LE PLUS. L’intelligence artificielle (IA) est un domaine de recherche en pleine expansion et promis à un grand avenir. Ses applications, qui concernent toutes les activités humaines, permettent notamment d’améliorer la qualité des soins. L’IA est en effet au cœur de la médecine du futur avec les opérations assistées, le suivi des patients à distance, les prothèses intelligentes, ou encore les traitements personnalisés grâce au recoupement de données (big data)…
CALACALIST. Viz.ai has raised a $100 million Series D round at a $1.2 billion valuation. The pace at which new companies have joined Israel’s unicorn list has significantly slowed in 2022 compared to last year, but Viz.ai’s announcement on Thursday also stands out due to its sector of activity.
The company develops an AI-powered disease detection and care coordination platform which is already in use in over 1,000 hospitals, serving millions of patients.
Over the past year, Viz.ai launched AI-driven solutions for aortic disease, pulmonary embolism, cerebral aneurysms, and is 510(k) pending for subdural hematoma.
Viz.ai co-founder and CTO Dr. David Golan told Calcalist that the company is comfortable with its new valuation. “Our new valuation reflects our growth very well. Our valuation has grown just as our revenue has grown.
We still haven’t used the money from our previous funding round and we now have money for the next four years. I’m not that interested in our valuation right now but rather where we will be in four years when our valuation is going to be far more significant,” explained Golan. “The investment market is tougher now than it was a year ago, but Viz brings something special to the table. Very few companies have a network with over 1,000 hospitals and the ability to generate significant business, which is something that gets VC funds excited.”
